Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 11/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6653750 | 0.84 | F2 (0.37) | F2L3MBTL1ALDH1A1MAPTHPGD | |
| SCHEMBL6653749 | 0.80 | F2 (0.40) | F2L3MBTL1MAPTSLC6A2SLC6A3 | |
| SCHEMBL6653752 | 0.80 | F2 (0.40) | F2L3MBTL1MAPTSLC6A2SLC6A3 | |
| SCHEMBL6653024 | 0.74 | KMT2A (0.48) | F2L3MBTL1ALDH1A1MAPTHPGD | |
| SCHEMBL6653550 | 0.72 | KMT2A (0.50) | F2L3MBTL1ALDH1A1MAPTHPGD | |
| SCHEMBL7310898 | 0.71 | KMT2A (0.59) | L3MBTL1ALDH1A1MAPTHPGDSLC6A2 | |
| SCHEMBL6655537 | 0.69 | RECQL (0.46) | F2ALDH1A1MAPTSLC6A2SLC6A3 | |
| SCHEMBL20759007 | 0.66 | KMT2A (0.50) | ALDH1A1MAPTHPGDSLC6A2SLC6A3 | |
| SCHEMBL19504138 | 0.66 | TDP1 (0.68) | L3MBTL1ALDH1A1MAPTHPGDSLC6A2 | |
| SCHEMBL6652205 | 0.66 | TDP1 (0.47) | L3MBTL1ALDH1A1MAPTHPGDSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1070049-B1 | BENZAMIDE AND SULFONAMIDE SUBSTITUTED AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2004-06-30 | — | — | EP | disclosed |
| US-6344486-B1 | ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-05 | — | — | US | disclosed |
| US-6344466-B2 | ANTITHROMBOTIC ACTIVITY, USE IN INHIBITING LOSS OF BLOOD PLATELETS, INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, INHIBITING FORMATION OF FIBRIN, ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS INC. | 2002-02-05 | — | — | US | disclosed |
| US-20010031870-A1 | Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors | SOLL RICHARD M (US) | 2001-10-18 | — | — | US | disclosed |
| EP-1070049-A1 | BENZAMIDE AND SULFONAMIDE SUBSTITUTED AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999051571-A1 | BENZAMIDE AND SULFONAMIDE SUBSTITUTED AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031870-A1 | Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors | PLG, F9, TFPI | F2 18/4885L3MBTL1 1362/4885ALDH1A1 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.